Submissions

Login or Register to make a submission.

Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
  • The manuscript has not been previously published, nor is it before another journal for consideration (or an explanation has been submitted in the Comments to the Editor).
  • Manuscript documents submitted are in the form of doc or docx files, with a maximum document size of 2MB. File naming: title_principal author name.
  • Articles must be submitted in English, with a structure and grammar that conform to the standards of good English writing.
  • Manuscripts are single-spaced; use Times New Roman 12-point font; italicize foreign language, not underline it (except with URL addresses); and tables, figures, and diagrams are placed in the text where they belong, not at the end. All tables/figures/diagrams are mentioned/called in the text.
  • If there are topics related to articles in the CDK journal, you may use those articles and include them in the reference list.
  • Manuscripts adhere to the style and bibliographic requirements outlined in the Author Guidelines, found in Manuscript Submission section.
  • In addition to submitting the manuscript, please also attach supporting documents including Cover Letter for Publication, Similarity Agreement Letter, and Informed Consent Case Report (specifically for Case Report manuscripts). Supporting documents are available at: https://bit.ly/AuthorformCDK. Please also attach a Letter of Reference/Permission for Mentioning the Institution (if the institution is mentioned in the manuscript).

Author Guidelines

Cermin Dunia Kedokteran (CDK) accepts manuscripts that discuss various aspects of medicine, pharmacy, and health, including research studies, systematic reviews, meta-analyses, and case reports. Submitted manuscripts must be intended for publication in CDK (i.e., not published in other journals); if they have been presented or discussed at a scientific meeting, please provide the meeting name, location, and date.
 
Currently, CDK accepts the following types of manuscripts: research, systematic review, meta-analyses, and evidence-based case report, and case report.
 
GENERAL GUIDELINES
Files in Ms. Word format. Starting in May 2026, CDK will accept only manuscripts written in English that follow proper structure and grammar. Manuscripts should be between 2,000 and 4,000 words (from abstract to conclusion) on A4 paper (210 mm x 297 mm), written using MS Word, Times New Roman font size 12 pt, single-spaced, justified. Manuscripts will be checked using the Turnitin application, and the maximum similarity index is 25%.
 
Research, systematic review, meta-analyses, and evidence-based case report manuscripts are organized into 4 subheadings: Introduction, Methods, Results, and Conclusion.
Case report manuscripts are organized into 4 subheadings: Introduction, Case, Discussion, and Conclusion. The author may adjust the subsections as needed.
The manuscript templates: https://bit.ly/4hfapVo

AUTHOR NAME AND INSTITUTION
Author(s) Name: Listed in full (no abbreviations), with an asterisk next to the author's name.
Author Institution: Information about the institution/faculty/institute where the author works, including the name of the city and country.

ABSTRACT AND KEYWORDS

Each manuscript must be accompanied by an abstract in English, along with 4–6 keywords listed in alphabetical order. The abstract should be 150–300 words.
 
The abstract should be written in 1 (one) paragraph, in the following format:
- Evidence-based research/systematic reviews/meta-analyses/evidence-based case reports: structured using the introduction, methods, results, conclusion (IMRAD) format
- Case reports: structured using the introduction, case, discussion, conclusion format

Tables/Graphs/Figures/Scheme

All tables, graphs, figures, and diagrams must be numbered sequentially using Arabic numerals (1, 2, 3, not A, B, C), and must be cited in the text. All tables, graphs, figures, and diagrams that support the content of the manuscript may be submitted separately in JPG format (they must be proportional and have good resolution, with a minimum resolution of 300 dpi at their original size). However, they must still appear in the manuscript.
 
Captions for figures/tables/graphs/diagrams must be written in 11-point Times New Roman font, with single spacing. Captions for figures and graphs must be placed below them, while table captions must be placed above them. Abbreviations used in tables, graphs, figures, or diagrams may have their full forms listed in the “Notes” section below the table, graph, figure, or diagram. Include citations for tables, graphs, figures, or diagrams; if they are personal documentation, include the author’s name (e.g., Documentation by…).

Citations
Citations in articles are written using Arabic numerals and are numbered in the order in which they appear in the article. Numbers are written in superscript format without parentheses, for example, “1”. References are written after punctuation marks, for example: 1–3.

Manuscript Declarations

After the Conclusion, include the following statements:

Ethics Statement

For research manuscripts, if the study involves human or animal subjects, provide approval from the appropriate ethics committee, including the registration number or official reference.

Informed Consent

If the study involves human participants, authors must state that informed consent to participate was obtained from all participants in accordance with applicable ethical requirements.

Consent for Publication

If the study includes institutional names, personal data, or identifiable images of individuals, authors must state that they obtained consent for publication from the institution, the patient, or the legal guardian. If not applicable, this should be explicitly declared.

Funding

Sources of funding or grants supporting the study must be clearly stated. If the study did not receive any financial support, this should be explicitly declared.

Author Contributions

For example: (Author name(s) or initial) contributed to the conception and design, collected data, and wrote the first draft of the manuscript. All authors reviewed and approved the manuscript.

Conflict of Interest

Authors must clearly declare whether any conflicts of interest exist, whether financial or non-financial. If no conflicts of interest exist, authors should state that they have no conflicts of interest.

Declaration on the Use of Artificial Intelligence (AI)

If artificial intelligence was used during the study or manuscript preparation, describe its use in detail, such as for data analysis, language editing, or draft preparation. Authors must affirm that the entire content of the manuscript has been reviewed, verified, and approved by the authors, and that full responsibility for the content remains with the authors.

Acknowledgments (optional)

List individuals or organizations that contributed to the study but do not qualify for authorship, such as supporting institutions, research assistants, or language editors, where available.

 

References
References are arranged according to the Vancouver rules. References are numbered in order of appearance in the manuscript. If there are six or fewer authors, list them all; if there are seven or more, list the first six and add “et al.”

There must be at least 15 references, published within the last 10 years or more recent. Try to include more primary references (at least 80%) than secondary references. For each reference, include the DOI (Digital Object Identifier) or PMID (PubMed identifier), if available.

 

Example of reference format according to Vancouver rules:

Journal
•    Standard

  1. Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008; 36(7646):701−4. doi: 10.1136/bmj.39497.500903.25.
  2. Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1−2):40−6. doi: 10.1016/s0006-8993(02)02445-9.

•    Organization as Author

Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopatreated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241−8. doi: 10.1001/archneur.62.2.241.

  • No Author Name

      21st century heart solution may have a sting in the tail. BMJ. 2002 Jul 27;325(7357):184. PMID: 12142303.

  • Volume with Supplements

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42(Suppl 2):S93−9. doi: 10.1046/j.1526-4610.42.s2.7.x.

  • Edition with Supplements

Glauser TA. Integrating clinical trial data into clinical practice. Neurology 2002;58(12 Suppl 7):6−12. doi: 10.1212/wnl.58.12_suppl_7.s6.

  • Electronic Journal

Alwan A, Maclean E. Monitoring and evaluation of health systems strengthening: a practical approach. Health Policy Plan [Internet]. 2020 [cited 2025 Jul 24];35(6):681–4. Available from: https://academic.oup.com/heapol/article/35/6/681/5855567.

Book

  • Sole Author/Editor Tunggal

Hoppert M. Microscopic techniques in biotechnology. Weinheim: Wiley-VCH; 2003.

  • More Than One Author/Editor

Gilstrap LC, Cunningham FG, Van Dorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

  • Edition with Volume

Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, editors. Wintrobes clinical hematology. 9th ed. Vol 2. Philadelphia: Lea & Febiger; 1993.

  • Chapters in a Book

Ford HL, Sclafani RA, DeGregori J. Cell cycle regulatory cascades. In: Stein GS, Pardee AB, editors. Cell cycle and growth control: biomolecular regulation and cancer. 2nd ed. Hoboken (NJ): Wiley-Liss; 2004. p. 42−67.

Conference Proceedings

Harnden P, Joe JK, Jones WG, editors. Germ cell tumours V: Proceedings of the 5th Germ Cell Tumour conference; 2001 Sep 13−15; Leeds, UK. New York: Springer; 2002.

Conference Paper

Christensen S, Oppacher F. An analysis of Koza’s computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming: EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 35−; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182−9.

 

MANUSCRIPT SUBMISSION
Manuscripts are sent to the editor in softcopy to this website.

CDK Editorial
Jl. Letjen Suprapto Kav. 4 Cempaka Putih, Jakarta 10510
E-mail: cdk@kalbe.co.id
Phone: (+6221) 42873888 - 89 ext. 2025

All statements in the manuscript are the responsibility of the author. The editorial board reserves the right to edit the wording without altering the content. Unpublished manuscripts will be returned to the author upon request. Given that CDK is currently accessible via the internet (online), published manuscripts will be more easily downloaded and utilized by a wider audience. Further correspondence will be conducted through the cdkjournal website.

The writings in this journal are the views/opinions of each author and do not necessarily represent the views or policies of the agency/institution where the author works.

Articles

Section default policy

Copyright Notice

Cermin Dunia Kedokteran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Copyright on any article is retained by the author(s).
  2. The author grants the journal, the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
  3. The article and any associated published material is distributed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Privacy Statement

This Privacy Policy ("Privacy Policy") describes the privacy practices of the cdkjournal website with respect to use of the website, which is intended for use by healthcare professionals, including cdkjournal's information and feature services (collectively, the "Feature Services"). This Privacy Policy does not apply to our properties and services that display a link to a different Privacy Policy.

We provide feature services as professional resources intended to enhance scientific insights to support higher quality services to Users. Users may choose whether or not to use the feature services. If the User chooses to use the feature services, it must agree to the cdkjournal Terms of Use which is a contract between cdkjournal and the User. By agreeing to the cdkjournal Terms of Use, the User confirms that it has read and understood this Privacy Policy.

By using the feature services, User acknowledges that we will store, use, and process User data from the cdkjournal website. If User does not want us to collect and use data about User as described in this Privacy Policy, then User should not use the feature services.